Roth Capital Has Bearish Estimate for Enovis FY2025 Earnings

Enovis Co. (NYSE:ENOV) – Equities researchers at Roth Capital reduced their FY2025 earnings per share estimates for Enovis in a note issued to investors on Thursday, February 27th. Roth Capital analyst J. Wittes now expects that the company will earn $3.24 per share for the year, down from their previous forecast of $3.31. The consensus estimate for Enovis’ current full-year earnings is $2.79 per share. Roth Capital also issued estimates for Enovis’ FY2026 earnings at $3.74 EPS.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.06. The firm had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%.

Separately, Needham & Company LLC lowered their price target on shares of Enovis from $65.00 to $64.00 and set a “buy” rating on the stock in a research report on Thursday.

Enovis Stock Performance

Shares of NYSE ENOV opened at $38.16 on Friday. Enovis has a one year low of $38.08 and a one year high of $63.96. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of -17.42 and a beta of 1.94. The stock’s fifty day moving average price is $44.90 and its two-hundred day moving average price is $44.34.

Institutional Trading of Enovis

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in Enovis by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company’s stock valued at $240,731,000 after purchasing an additional 75,348 shares in the last quarter. Diamond Hill Capital Management Inc. increased its holdings in Enovis by 7.8% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 3,004,694 shares of the company’s stock valued at $129,352,000 after buying an additional 218,660 shares during the period. DAVENPORT & Co LLC raised its position in shares of Enovis by 6.0% in the 4th quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company’s stock valued at $121,181,000 after buying an additional 157,216 shares in the last quarter. Royce & Associates LP lifted its holdings in shares of Enovis by 2.8% during the 4th quarter. Royce & Associates LP now owns 2,470,576 shares of the company’s stock worth $108,409,000 after acquiring an additional 66,891 shares during the period. Finally, State Street Corp boosted its position in shares of Enovis by 4.3% during the 3rd quarter. State Street Corp now owns 1,647,220 shares of the company’s stock worth $70,913,000 after acquiring an additional 68,190 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.